hydroxychloroquine has been researched along with Cerebrovascular Disorders in 9 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient in her late 50s with antiphospholipid syndrome presented to general ophthalmology clinic for annual hydroxychloroquine retinopathy screening." | 4.12 | Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate. ( Baxter, SL; Delavar, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Delavar, A | 3 |
| Baxter, SL | 3 |
| El Boussadani, B | 1 |
| Benajiba, C | 1 |
| Aajal, A | 1 |
| Ait Brik, A | 1 |
| Ammour, O | 1 |
| El Hangouch, J | 1 |
| Oussama, O | 1 |
| Oussama, B | 1 |
| Tahiri, N | 1 |
| Raissuni, Z | 1 |
| McLaurin, EY | 1 |
| Holliday, SL | 1 |
| Williams, P | 1 |
| Brey, RL | 1 |
| Bouchier-Hayes, D | 1 |
| Turpie, AG | 1 |
| Hirsh, J | 3 |
| Dettori, AG | 1 |
| Pini, M | 1 |
| Quintavalla, R | 1 |
| Harker, LA | 1 |
| Gent, M | 2 |
| Genton, E | 2 |
| Didisheim, P | 1 |
| Kazmier, FJ | 1 |
| Fuster, V | 1 |
5 reviews available for hydroxychloroquine and Cerebrovascular Disorders
| Article | Year |
|---|---|
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1
Topics: Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiomyopathies; Cardiovascular Dis | 2020 |
Platelet suppressive therapy.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coro | 1978 |
[Treatment with antiplatelet drugs. Current status of knowledge].
Topics: Aspirin; Blood Platelet Disorders; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dextrans | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
2 trials available for hydroxychloroquine and Cerebrovascular Disorders
| Article | Year |
|---|---|
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
The current status of platelet suppressive drugs in the treatment of thrombosis.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cardiac Catheterization; Cell Surviva | 1975 |
3 other studies available for hydroxychloroquine and Cerebrovascular Disorders
| Article | Year |
|---|---|
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant | 2005 |
Drugs in the treatment of thrombo-embolic disease--part I.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Carotid Artery Diseases; Cerebrovasc | 1983 |